-
TRUSTED AU LABORATORY
-
26 Mark Rd. Elizabeth South, SA - 5112
-
Same day delivery
Pull the syringe to:
(0.100ml)
This calculator is provided as a reference tool for research purposes only. Always follow your institution’s safety protocols when handling research compounds.
CJC-1295 with DAC 10mg is a research peptide commonly studied in growth hormone-releasing hormone pathway research. It belongs to a class of synthetic GHRH analogue peptides that are examined for their interaction with growth hormone signalling, IGF-1 response models and extended-release peptide behaviour.
The “DAC” in CJC-1295 with DAC stands for Drug Affinity Complex. In research terms, this modification is designed to extend the peptide’s activity profile by supporting albumin binding, which may allow the compound to remain active for longer in controlled study models compared with shorter-acting GHRH analogues. A published clinical study reported an estimated CJC-1295 half-life of 5.8 to 8.1 days in its study setting.
This product is supplied for laboratory research use only. It is not a medicine, supplement, cosmetic product, therapeutic product or injectable product for human use.
| Product Detail | Information |
|---|---|
| Product name | CJC-1295 with DAC |
| Size | 10mg |
| Product type | Research peptide |
| Research category | Growth Hormone Research |
| Peptide class | Modified GHRH analogue |
| Key research interest | Extended growth hormone-releasing hormone signalling |
| Form | Lyophilised powder |
| Intended use | Laboratory research only |
| Human use | Not for human consumption, administration or injection |
| Documentation | Certificate of Analysis should be checked before use |
| Component | Research Class | General Research Role |
|---|---|---|
| CJC-1295 | Modified GHRH analogue | Studied for growth hormone-releasing hormone receptor pathway activity |
| DAC modification | Drug Affinity Complex | Studied for extended activity and albumin-binding behaviour |
| Lyophilised peptide preparation | Freeze-dried peptide format | Supports stability before reconstitution when stored correctly |
The exact product identity, purity and batch information should always be confirmed through the supplier documentation and Certificate of Analysis. Researchers should not rely on product name alone when confirming peptide identity.
CJC-1295 with DAC is studied as a long-acting analogue of growth hormone-releasing hormone. GHRH is naturally involved in signalling the pituitary gland to release growth hormone. In research models, CJC-1295 is examined for how it interacts with this pathway and how extended peptide activity may influence downstream GH and IGF-1 signalling.
The DAC modification is the main feature that separates CJC-1295 with DAC from CJC-1295 No DAC. While No DAC versions are generally discussed as shorter-acting research compounds, CJC-1295 with DAC is studied for its longer activity profile and albumin-binding behaviour.
In one published study, CJC-1295 was associated with dose-dependent increases in mean plasma growth hormone concentrations for 6 days or more and IGF-1 concentrations for 9 to 11 days in the study setting. This should be understood as research literature context only, not as a product claim for unapproved human use.
| Research Area | CJC-1295 with DAC |
|---|---|
| Main pathway | Growth hormone-releasing hormone pathway |
| Research receptor focus | GHRH receptor signalling |
| Key modification | Drug Affinity Complex |
| Common research interest | Extended GH and IGF-1 signalling models |
| Compared with No DAC version | Generally studied for longer activity profile |
| Product limitation | Research use only, not approved for human use |
| Feature | CJC-1295 with DAC | CJC-1295 No DAC |
|---|---|---|
| DAC modification | Yes | No |
| Research activity profile | Studied as longer-acting | Studied as shorter-acting |
| Common research interest | Extended GHRH pathway activity | Pulsatile or shorter-duration GHRH pathway research |
| Albumin binding | Associated with DAC design | Not the same DAC-linked profile |
| Product positioning | Long-acting GHRH analogue research | Short-acting GHRH analogue research |
| Human-use status | Research use only | Research use only |
| Common Online Claim | Safer Research-Use Wording |
|---|---|
| Muscle growth | Studied in relation to growth hormone and IGF-1 signalling pathways |
| Anti-ageing | Studied in endocrine and cellular signalling research models |
| Recovery | Studied in laboratory models connected to GH pathway activity |
| Fat loss | Studied within metabolic and endocrine signalling contexts |
| Sleep support | Studied in relation to endocrine rhythm and GH-related research pathways |
| Performance enhancement | Not an approved or appropriate product claim |
CJC-1295 with DAC 10mg is not intended to diagnose, treat, cure or prevent any disease. It is not supplied for body enhancement, muscle growth, fat loss, anti-ageing, recovery, sleep improvement, athletic performance or general wellness use.
All information on this page is provided for laboratory research and product handling context only.
There is no universal recommended dilution for CJC-1295 with DAC 10mg. Dilution depends on the research protocol, required working concentration, assay design, solvent compatibility, storage method and validated laboratory procedure.
For research concentration planning only, the basic formula is:
Total peptide amount divided by diluent volume equals final concentration.
| Diluent Added to 10mg Vial | Final Concentration |
|---|---|
| 1mL | 10mg/mL |
| 2mL | 5mg/mL |
| 2.5mL | 4mg/mL |
| 3mL | 3.33mg/mL |
| 4mL | 2.5mg/mL |
| 5mL | 2mg/mL |
| 10mL | 1mg/mL |
These are research concentration examples only. They are not human dosing instructions and must not be used to calculate injection quantities.
Before handling CJC-1295 with DAC 10mg in a laboratory setting, make sure all materials, documentation and clean handling conditions are prepared.
| Item | Purpose |
|---|---|
| Product vial | Contains lyophilised CJC-1295 with DAC |
| Certificate of Analysis | Confirms batch-level testing information |
| Suitable research-grade diluent | Used to prepare a working research solution |
| Sterile lab consumables | Helps reduce contamination risk |
| Personal protective equipment | Gloves, lab coat and eye protection |
| Alcohol wipes or approved disinfectant | Used for surface and vial-top preparation |
| Laboratory labels | Records concentration, date, batch and handler details |
| Cold storage access | Supports correct storage after preparation |
| Disposal container | Used for compliant laboratory waste disposal |
The following is a general laboratory handling framework only. Always follow the product Certificate of Analysis, supplier documentation, SDS, institutional procedures and validated research protocol.
Check the product label, batch number, Certificate of Analysis and storage requirements before handling the vial.
Use a clean laboratory workspace. Wear appropriate PPE and disinfect the bench surface, vial top and any required equipment.
If the vial has been stored cold, allow it to equilibrate according to laboratory procedure before opening or reconstitution. Avoid condensation entering the vial.
Add the selected research-grade diluent slowly down the inside wall of the vial. Avoid forceful spraying directly onto the lyophilised powder.
Gently swirl or roll the vial until the powder is dissolved. Avoid aggressive shaking, unnecessary vortexing or foaming unless a validated protocol specifically allows it.
Check the solution for cloudiness, visible particles, unusual colour changes or undissolved material. If anything appears abnormal, quarantine the vial and check supplier documentation.
Label the vial or aliquots with the product name, concentration, diluent used, date prepared, batch number and researcher initials.
Place the reconstituted solution into the required storage condition as soon as possible. Avoid unnecessary warming, cooling or repeated freeze-thaw cycles.
Some lyophilised peptide products may take time to fully hydrate. Dissolution should always be handled gently and according to laboratory protocol.
| Issue | What It May Indicate | Safer Response |
|---|---|---|
| Powder clinging to vial wall | Static or lyophilisation residue | Allow more contact time with diluent |
| Small particles remain | Incomplete hydration | Continue gentle swirling |
| Cloudy solution | Possible incompatibility or contamination | Stop and check documentation |
| Foaming | Too much agitation | Let the solution settle and avoid shaking |
| Colour change | Possible degradation or contamination | Do not continue without supplier guidance |
| Storage Factor | Guidance |
|---|---|
| Product form | Lyophilised powder |
| Storage condition | Follow supplier label and Certificate of Analysis |
| Light exposure | Protect from unnecessary light exposure |
| Moisture exposure | Keep sealed until use |
| Temperature changes | Avoid repeated temperature cycling |
| Handling | Minimise unnecessary opening or vial puncture |
| Storage Factor | Guidance |
|---|---|
| Storage condition | Follow validated research protocol |
| Labelling | Record concentration, date, diluent and batch number |
| Freeze-thaw cycles | Avoid repeated freeze-thaw exposure |
| Aliquoting | Use small research aliquots where appropriate |
| Contamination control | Use clean laboratory technique |
| Disposal | Dispose according to laboratory waste procedures |
Peptides may be sensitive to temperature, light, pH, agitation and contamination. Storage conditions should be confirmed through supplier documentation or the laboratory’s validated method.
This page does not provide human dosing, injection instructions, injection schedules or administration guidance.
CJC-1295 with DAC 10mg is not supplied for human or animal administration. It is a laboratory research-use product only.
The TGA warns that unapproved peptide products promoted online may be poorly labelled, contaminated or unsafe, and that they have not been assessed for safety, quality or effectiveness.
For research settings, any measured aliquots should be prepared according to the concentration required by the approved research protocol. All calculations should be checked, documented and traceable.
| Planning Item | What to Record |
|---|---|
| Final concentration | Total peptide amount and diluent volume |
| Working solution | Concentration used in the research protocol |
| Aliquot volume | Volume transferred into each labelled lab tube |
| Batch details | Product batch, CoA and preparation date |
| Storage location | Fridge, freezer or other controlled storage area |
| Handler details | Researcher name or initials |
| Preparation date | Date and time of reconstitution |
| Disposal date | When the aliquot should no longer be used |
Correct handling is important for research consistency, contamination control and product traceability. Most mistakes occur when products are not labelled clearly, concentration calculations are not recorded or storage conditions are not followed.
| Always | Why It Matters |
|---|---|
| Check the Certificate of Analysis | Confirms batch-level information |
| Use PPE | Reduces contamination and exposure risk |
| Label every vial and aliquot | Prevents mix-ups |
| Record concentration calculations | Supports traceability |
| Use clean laboratory technique | Reduces contamination risk |
| Follow institutional protocols | Keeps handling consistent and auditable |
| Store according to documentation | Helps protect peptide integrity |
| Dispose of lab waste correctly | Supports safety and compliance |
| Never | Why It Is Risky |
|---|---|
| Never use for self-injection | Product is research use only |
| Never make human dosing claims | Creates safety and compliance risk |
| Never assume purity without CoA | Batch quality must be documented |
| Never use a damaged or unlabelled vial | Identity and sterility may be uncertain |
| Never shake aggressively | May affect peptide integrity |
| Never use random solvents | May damage the peptide or alter research results |
| Never leave reconstituted product unlabelled | Creates traceability risk |
| Never rely on social media protocols | They may be inaccurate, unsafe or non-compliant |
The table below is for concentration planning only. It does not represent dosage, injection quantity or recommended administration.
| Total Vial Amount | Diluent Volume | Final Concentration |
|---|---|---|
| 10mg | 1mL | 10mg/mL |
| 10mg | 2mL | 5mg/mL |
| 10mg | 2.5mL | 4mg/mL |
| 10mg | 3mL | 3.33mg/mL |
| 10mg | 4mL | 2.5mg/mL |
| 10mg | 5mL | 2mg/mL |
| 10mg | 10mL | 1mg/mL |
If a researcher adds 2mL of suitable research-grade diluent to a 10mg vial, the resulting concentration is 5mg/mL.
This calculation is for research concentration planning only. It is not a human or animal dosing example.
DAC stands for Drug Affinity Complex. In research contexts, this modification is associated with extended activity and albumin-binding behaviour.
No. CJC-1295 with DAC is generally studied as a longer-acting GHRH analogue, while CJC-1295 No DAC is usually discussed as a shorter-acting version. Product identity should always be confirmed through supplier documentation and analytical testing.
No. This product is supplied for laboratory research use only. It should not be described as approved for therapeutic, cosmetic, body enhancement or injectable use.
No. This product should not be promoted for muscle growth, weight loss, anti-ageing, performance enhancement, recovery, sleep improvement or general wellness outcomes.
A Certificate of Analysis provides batch-level testing information. It helps researchers verify product identity, purity and quality documentation before use in a research setting.
| Resource | Why It Is Useful |
|---|---|
| TGA guidance on unapproved peptide products | Important Australian regulatory context for peptide products, advertising and supply responsibilities |
| TGA warning on importing unapproved peptides | Explains safety concerns around poorly labelled peptide powders and injectable products |
| PubMed research on CJC-1295 | Useful background on controlled research involving CJC-1295 and GH/IGF-1 signalling |
Research Use Only: CJC-1295 with DAC 10mg is supplied strictly for laboratory research purposes. It is not intended for human or animal consumption, injection, therapeutic use, cosmetic use, diagnostic use or performance enhancement. Information on this page is provided for research education and product handling context only. Always follow applicable laws, institutional procedures, supplier documentation and qualified laboratory protocols.
